AbbVie at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
AbbVie exhibits at Booth 1613 at ASH 2026 in New Orleans. Its presence centres on acute myeloid leukemia and BPDCN, supporting symposia on current AML management and on BPDCN diagnosis with CD123-directed therapies. It also supports a symposium on next steps in relapsed myeloma, including T-cell engagers and newer CAR T.
| Organization | ASH 2026 Attendance |
|---|---|
AbbVie North Chicago, IL | |
Global biopharmaceutical company discovering and developing medicines for serious diseases across several therapeutic areas, including blood cancers. | Booth Exhibiting at Booth 1613 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. |
Instantly find 20 buyers from AbbVie
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction